oxaliplatin liposomal (L-OHP) / Mebiopharm - LARVOL DELTA

NAPOLI-3: first-line NALIRIFOX in metastatic pancreatic ductal adenocarcinoma (YouTube) - "Zev Wainberg, MD...presents findings from the Phase III NAPOLI-3 trial (NCT04083235), which compared liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) to nab-paclitaxel with gemcitabine in previously untreated patients with metastatic pancreatic ductal adenocarcinoma. Patients receiving NALIRIFOX demonstrated superior overall survival and progression-free survival, providing a promising first-line treatment for a group of patients with limited options. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA."

Interview • Video

Novel Combination May Break Outcomes Stalemate in Pancreatic Cancer (OncLive) - '"[It has been] 2 decades since the first drug [for patients with pancreatic cancer] was approved by the FDA-gemcitabine-and since then our progress in pancreatic cancer has been really very unsatisfactory,' said Philip A. Philip, MD, PhD, in an interview with OncologyLive. 'After 2 decades or so, we have only 2 regimens that we use: one is the gemcitabine and Abraxane [nab-paclitaxel] and the other one is a triplet called FOLFIRINOX [leucovorin, 5-fluorouracil, irinotecan hydrochloride, and oxaliplatin].'"

Media quote